Shattuck Labs is a clinical-stage biopharmaceutical company engaged in developing dual-sided fusion proteins, including its Agonist Redirected Checkpoint and GADLEN™ platforms, as classes of biologic medicines capable of multifunctional activity with applications in oncology and inflammatory diseases. Co.'s product candidate SL-172154, which is in Phase 1 clinical trial for the treatment of patients with ovarian cancer. Co.'s second product candidate, SL-279252, which is developed to inhibit the PD-1/PD-L1 interaction and activate the OX40 costimulatory receptor and is in Phase 1 clinical trial in patients with solid tumors and lymphoma. Co. has several compounds in preclinical development.